


# Medilink Case Study

www.medilink.co.uk



## RD Biomed Peptest™



**Turning world-class science** into consumer relevant propositions, Hull based company RD Biomed has launched their latest innovation – Peptest™.

The diagnostic test measures the amount of pepsin in the stomach - an enzyme used as an indicator of reflux disease; the illness that causes 7000 deaths annually.

### Benefits

Traditional methods of detecting gastric reflux are highly invasive and require 24 hour monitoring. Peptest™ is around 25% more accurate, a more acceptable experience for the patient, and will save NHS Trusts both time and money.

By rapidly diagnosing gastric reflux, Peptest improves the care of patients with reflux associated disease and ensures that inappropriate drug treatment and unnecessary referrals or follow ups are avoided.

### Innovation

A lateral flow device, similar in appearance to the common pregnancy tests, the Peptest™ uses 2 unique monoclonal antibodies - developed at laboratories in Hull.

Peptest™ permits the non-invasive, pH independent identification of patients suffering from gastric reflux.

It detects pepsin in clinical samples obtained from the upper digestive tract and the respiratory system. The presence of pepsin in these samples is a reliable marker for the reflux of gastric juice.



### Collaboration

Collaboration is critical to the success of RD Biomed. Fusing technical knowledge with clinical expertise is essential to the progression of innovation in healthcare, so working with clinicians is fundamental to the development of the company.

Working with leading clinicians in the fields of gastroenterology and wound care has been vital in ensuring new products are developed with the endorsement of global key opinion leaders.

Working with regional organisations has also been fundamental. RD Biomed have collaborated with Yorkshire based companies to access a diverse range of services including product design, manufacturing, marketing and legal/intellectual property services.

Being able to engage in various collaborations has allowed RD Biomed to accelerate the development of its product portfolio.

“Without the financial assistance of Yorkshire Forward’s grant for Research and Development, delivering our products to market would have been a real barrier. Thankfully, working with organisations such as Medilink Yorkshire and Humber has enabled us to find a clear route to market and knowledgeable assistance on call if we need it.”

Craig Richardson,  
Managing Director, RD Biomed

### About RD Biomed

RD Biomed are innovators in healthcare product development. They are currently developing a robust pipeline of products that provide innovative solutions to satisfy unmet clinical needs.

Focussing on gastroenterology and wound management, RD Biomed develops products that identify, prevent and treat various medical conditions. These products are marketed either directly by RD Biomed or by partner companies under exclusive license.



**Medilink**  
Yorkshire & Humber

Medilink Yorkshire and Humber  
Building 1  
3 Smithy Wood Drive  
Smithy Wood Business Park  
Sheffield  
S35 1QN

Tel: 0114 232 9292  
Fax: 0114 245 6820  
www.medilink.co.uk



Connect



Innovate



Communicate



Internationalise



Communities